Tapimmune, Inc. (TPIV) Reports FY17 EPS Loss of $1.16

Note: EPS may not be comparable

Tapimmune, Inc. (NASDAQ: TPIV) reported FY17 EPS of ($1.16).

Recent Corporate and Clinical Developments:

• Published long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200
• Commenced dosing in 280-patient, grant-funded Phase 2 study of TPIV200 in women with advanced TNBC
• Enhanced IP portfolio for PolyStart™ technology, expanding to cover any polypeptide sequences comprising poly-antigen arrays (PAAs)
• Appointed Dr. Richard Kenney as Acting Chief Medical Officer

For earnings history and earnings-related data on Tapimmune, Inc. (TPIV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Movano (MOVE) Misses Q2 EPS by 195c